| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C0001675> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C0003062> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C0013072> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C0039005> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C0325192> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C2713498> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/34181475_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'Department of Infectious Disease, Nantes University Hospital, Nantes, France.\', \'INSERM CIC1413, Nantes University Hospital, Nantes, France.\', \'Clinical Pharmacology Department, CHU Nantes, Nantes, France.\', \'Xenothera, Nantes, France.\', \'Laboratoire d\'Immunologie, CIMNA, CHU Nantes, Nantes, France.\', \'Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, ITUN, CHU Nantes, Nantes, France.\', \'Institut Pierre Louis d\'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, AP-HP, Hôpital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, Paris, France.\', \'Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire d\'Angers, Angers, France.\', \'Virology Laboratory University Hospital, Nantes, France.\', \'Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France.\', \'Département des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.\', \'CHU Nantes, Sponsor Department, Nantes, France.\', \'CHU Nantes, Pharmacy Department, Nantes, France.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Ader_Florence> <https://research.tib.eu/covid-19/entity/Berly_Laetitia> <https://research.tib.eu/covid-19/entity/Brouard_Sophie> <https://research.tib.eu/covid-19/entity/Chiffoleau_Anne> <https://research.tib.eu/covid-19/entity/Dailly_Eric> <https://research.tib.eu/covid-19/entity/Danger_Richard> <https://research.tib.eu/covid-19/entity/Dubee_Vincent> <https://research.tib.eu/covid-19/entity/Duvaux_Odile> <https://research.tib.eu/covid-19/entity/Ferre_Virginie> <https://research.tib.eu/covid-19/entity/Flet_Laurent> <https://research.tib.eu/covid-19/entity/Gaborit_Benjamin> <https://research.tib.eu/covid-19/entity/Jobert_Alexandra> <https://research.tib.eu/covid-19/entity/Josien_R%C3%A9gis> <https://research.tib.eu/covid-19/entity/Lacombe_Karine> <https://research.tib.eu/covid-19/entity/Le_Thuaut_Aur%C3%A9lie> <https://research.tib.eu/covid-19/entity/Omnes_Anne> <https://research.tib.eu/covid-19/entity/Raffi_Fran%C3%A7ois> <https://research.tib.eu/covid-19/entity/Vanhove_Bernard> <https://research.tib.eu/covid-19/entity/Vibet_Marie-Anne>
?:doi	<https://research.tib.eu/covid-19/entity/10.1128/AAC.01237-21>
?:doi	10.1128/AAC.01237-21
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Clinical_Trial%2C_Phase_II> <https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Randomized_Controlled_Trial> <https://research.tib.eu/covid-19/entity/Research_Support%2C_Non-U.S._Gov%27t>
?:journal	Antimicrobial agents and chemotherapy
is ?:pmid of	<https://research.tib.eu/covid-19/entity/34181475>
?:pmid	<https://research.tib.eu/covid-19/entity/34181475>
?:pmid	34181475
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	2.291
?:rankingScore_hIndex	226
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/C0312586_ASSOCIATED_WITH_C0032285>
?:title	Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2021

Property

Value

is ?:annotates of

?:authorAffiliation

[\'Department of Infectious Disease, Nantes University Hospital, Nantes, France.\', \'INSERM CIC1413, Nantes University Hospital, Nantes, France.\', \'Clinical Pharmacology Department, CHU Nantes, Nantes, France.\', \'Xenothera, Nantes, France.\', \'Laboratoire d\'Immunologie, CIMNA, CHU Nantes, Nantes, France.\', \'Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, ITUN, CHU Nantes, Nantes, France.\', \'Institut Pierre Louis d\'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, AP-HP, Hôpital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, Paris, France.\', \'Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire d\'Angers, Angers, France.\', \'Virology Laboratory University Hospital, Nantes, France.\', \'Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France.\', \'Département des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.\', \'CHU Nantes, Sponsor Department, Nantes, France.\', \'CHU Nantes, Pharmacy Department, Nantes, France.\']

?:citedBy

-1

?:creator

?:doi

<https://research.tib.eu/covid-19/entity/10.1128/AAC.01237-21>

?:doi

10.1128/AAC.01237-21

?:hasPublicationType

?:journal

Antimicrobial agents and chemotherapy

is ?:pmid of

<https://research.tib.eu/covid-19/entity/34181475>

?:pmid

<https://research.tib.eu/covid-19/entity/34181475>

?:pmid

34181475

?:publication_isRelatedTo_Disease

<https://research.tib.eu/covid-19/entity/Covid-19>

?:rankingScore_SJR

2.291

?:rankingScore_hIndex

is ?:relation_isRelatedTo_publication of

<https://research.tib.eu/covid-19/entity/C0312586_ASSOCIATED_WITH_C0032285>

?:title

Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.

?:type

?:year

2021

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/34181475>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/34181475>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

Metadata